BioLife will increase the visible value of Bioscience resources worldwide by combining 3 automated systems for messaging, transaction processing and smart contracts into a digital ecosystem for the Bioscience industry.BioLife will build a global high-end biomedical resources DLT platform for products, services and data to provide safe, private, reliable, efficient and economical service access for biomedical resource owners, patients and investors.A consortium chain based on ACChain, BioLife is an on-chain asset digitization and private handler for patients, investors and owners of global biomedical resources. BioLife’s digital ecosystem is a distributed, adaptive, open-source, peer to peer system. Its blockchain properties of self-organization, scalability, interoperability and resilience were inspired by the very natural ecosystems from which Swiss Serolab derives its health care solutions. Distribution, circulation and service placement are the three basic applications of the BioLife digital ecosystem.
The BioLife Service Platform will provide digital portals for pharmaceutical companies, biomedical institutions and equipment manufacturers and use blockchain technology to record the entire process of the biomedical services supply chain, treatment processes and results. BioLife’s adoption of DLT as its technology backbone will introduce the following benefits to all areas of the biomedical services sector that are impacted by BioLife Data: heightened security and resistance to tampering, protection of personally identifiable information and other elements of privacy (including protection against data scrapes), elimination of any single point of failure and disintermediation of third parties (thereby reducing transaction times and eliminating third party transaction fees).
In the future, BioLife will be extended to smartwear for the daily collection of physical health data. It can achieve realtime monitoring and early warning of a patient’s physical health through artificial intelligence, machine learning and big data technology. At the same time, BioLife will also head in the direction of biomedical science and research, providing a large amount of sample data for scientific research institutions. This will establish a shared data platform among scientific research institutions, recording biomedical scientific research results to ensure the clarity of ownership and accurate return of scientific research results to reduce R&D duplication and to enjoy the fruitful results. BioLife is aiming to promote the progress and sustainable development of life science and technology.
Attention. There is a risk that unverified members are not actually members of the team
$138 480 473
This offer is based on information provided solely by the offeror and other publicly available information. The token sale or exchange event is entirely unrelated to ICOholder and ICOholder has no involvement in it (including any technical support or promotion). Token sales listed from persons that ICOholder has no relationship with are shown only to help customers keep track of the activity taking place within the overall token sector. This information is not intended to amount to advice on which you should rely. You must obtain professional or specialist advice or carry out your own due diligence before taking, or refraining from, any action on the basis of the content on our site. Any terms and conditions entered into by contributors in respect of the acquisition of Tokens are between them and the issuer of the Token and ICOholder is not the seller of such Tokens. ICOholder has no legal responsibility for any representations made by third parties in respect of any Token sale and any claim for breach of contract must also be made directly against the Token issuing entity listed herein.
If you have any concerns about the nature, propriety or legality of this token sale or the persons involved in it please contact [email protected] with detailed information about your concerns.